Study of primary biliary cholangitis in Switzerland
Part of Digestive system clinical trials.
This study follows adults with primary biliary cholangitis (a long-term liver and bile duct condition). It may help doctors better understand the disease in different people, including those identified by specific blood antibody tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with primary biliary cholangitis
- Your diagnosis is based on established European liver guidelines
- You may qualify if you have certain related blood antibodies (anti-mitochondrial and/or PBC-specific anti-nuclear antibodies)
- You live in Switzerland
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a national registry (database) of adults in Italy living with primary biliary cholangitis (PBC). Being included can help doctors better understand the condition and improve future care.
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
This study observes people with primary biliary cholangitis (PBC) to learn more about the disease and what factors might make it worse over time. It uses your medical history and liver biopsy results to understand how PBC progresses.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial is testing a “find patients who are missing from care” program for people with primary biliary cholangitis (PBC). It may help connect you to follow-up sooner if you’ve been hard to reach through usual clinic records.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.